|
Gene: EXOC4 |
Gene summary for EXOC4 |
Gene summary. |
Gene information | Species | Human | Gene symbol | EXOC4 | Gene ID | 60412 |
Gene name | exocyst complex component 4 | |
Gene Alias | SEC8 | |
Cytomap | 7q33 | |
Gene Type | protein-coding | GO ID | GO:0001704 | UniProtAcc | Q6NX51 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
60412 | EXOC4 | CCI_2 | Human | Cervix | CC | 3.60e-07 | 8.29e-01 | 0.5249 |
60412 | EXOC4 | CCI_3 | Human | Cervix | CC | 1.17e-14 | 1.30e+00 | 0.516 |
60412 | EXOC4 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.59e-19 | -5.61e-01 | 0.0155 |
60412 | EXOC4 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.87e-03 | -4.48e-01 | -0.1808 |
60412 | EXOC4 | HTA11_2951_2000001011 | Human | Colorectum | AD | 8.22e-06 | -9.73e-01 | 0.0216 |
60412 | EXOC4 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.72e-04 | 4.25e-01 | -0.1954 |
60412 | EXOC4 | HTA11_3361_2000001011 | Human | Colorectum | AD | 7.10e-13 | -7.06e-01 | -0.1207 |
60412 | EXOC4 | HTA11_5212_2000001011 | Human | Colorectum | AD | 7.89e-06 | -6.41e-01 | -0.2061 |
60412 | EXOC4 | HTA11_5216_2000001011 | Human | Colorectum | SER | 4.35e-03 | -7.68e-01 | -0.1462 |
60412 | EXOC4 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.08e-06 | -3.51e-01 | -0.0179 |
60412 | EXOC4 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.50e-09 | -5.57e-01 | 0.096 |
60412 | EXOC4 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.03e-02 | -4.88e-01 | 0.0528 |
60412 | EXOC4 | HTA11_6801_2000001011 | Human | Colorectum | SER | 1.56e-02 | -5.59e-01 | 0.0171 |
60412 | EXOC4 | HTA11_10711_2000001011 | Human | Colorectum | AD | 3.49e-10 | -4.42e-01 | 0.0338 |
60412 | EXOC4 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.90e-10 | -4.45e-01 | 0.0674 |
60412 | EXOC4 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.35e-06 | -3.80e-01 | 0.294 |
60412 | EXOC4 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 4.76e-04 | 6.58e-01 | 0.3487 |
60412 | EXOC4 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.37e-14 | 9.45e-01 | 0.281 |
60412 | EXOC4 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.55e-15 | -5.44e-01 | 0.3005 |
60412 | EXOC4 | A015-C-203 | Human | Colorectum | FAP | 4.12e-47 | -8.42e-01 | -0.1294 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002240611 | Liver | HCC | membrane docking | 57/7958 | 86/18723 | 7.14e-06 | 8.47e-05 | 57 |
GO:014005611 | Liver | HCC | organelle localization by membrane tethering | 49/7958 | 77/18723 | 1.46e-04 | 1.18e-03 | 49 |
GO:0048278 | Liver | HCC | vesicle docking | 34/7958 | 59/18723 | 1.36e-02 | 4.84e-02 | 34 |
GO:00105066 | Lung | IAC | regulation of autophagy | 65/2061 | 317/18723 | 4.97e-07 | 3.14e-05 | 65 |
GO:00068926 | Lung | IAC | post-Golgi vesicle-mediated transport | 27/2061 | 104/18723 | 1.54e-05 | 4.49e-04 | 27 |
GO:00162366 | Lung | IAC | macroautophagy | 51/2061 | 291/18723 | 5.30e-04 | 7.49e-03 | 51 |
GO:00516506 | Lung | IAC | establishment of vesicle localization | 32/2061 | 161/18723 | 6.53e-04 | 8.87e-03 | 32 |
GO:00516566 | Lung | IAC | establishment of organelle localization | 64/2061 | 390/18723 | 7.12e-04 | 9.50e-03 | 64 |
GO:00516486 | Lung | IAC | vesicle localization | 34/2061 | 177/18723 | 8.53e-04 | 1.09e-02 | 34 |
GO:00481937 | Lung | IAC | Golgi vesicle transport | 49/2061 | 296/18723 | 2.35e-03 | 2.28e-02 | 49 |
GO:00162415 | Lung | IAC | regulation of macroautophagy | 27/2061 | 141/18723 | 2.89e-03 | 2.60e-02 | 27 |
GO:00988766 | Lung | IAC | vesicle-mediated transport to the plasma membrane | 26/2061 | 136/18723 | 3.50e-03 | 2.96e-02 | 26 |
GO:00604852 | Lung | IAC | mesenchyme development | 47/2061 | 291/18723 | 4.61e-03 | 3.64e-02 | 47 |
GO:00068935 | Lung | IAC | Golgi to plasma membrane transport | 14/2061 | 60/18723 | 4.82e-03 | 3.74e-02 | 14 |
GO:00224066 | Lung | IAC | membrane docking | 18/2061 | 86/18723 | 5.26e-03 | 3.99e-02 | 18 |
GO:000689212 | Lung | AIS | post-Golgi vesicle-mediated transport | 26/1849 | 104/18723 | 6.59e-06 | 2.93e-04 | 26 |
GO:001050612 | Lung | AIS | regulation of autophagy | 55/1849 | 317/18723 | 2.46e-05 | 8.04e-04 | 55 |
GO:005165012 | Lung | AIS | establishment of vesicle localization | 31/1849 | 161/18723 | 2.15e-04 | 4.36e-03 | 31 |
GO:005164812 | Lung | AIS | vesicle localization | 33/1849 | 177/18723 | 2.56e-04 | 4.96e-03 | 33 |
GO:006048511 | Lung | AIS | mesenchyme development | 47/1849 | 291/18723 | 5.06e-04 | 8.28e-03 | 47 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa05132110 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa051321 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa051322 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
hsa051323 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
hsa051324 | Colorectum | MSS | Salmonella infection | 92/1875 | 249/8465 | 5.23e-08 | 9.74e-07 | 5.97e-07 | 92 |
hsa051325 | Colorectum | MSS | Salmonella infection | 92/1875 | 249/8465 | 5.23e-08 | 9.74e-07 | 5.97e-07 | 92 |
hsa051326 | Colorectum | MSI-H | Salmonella infection | 43/797 | 249/8465 | 5.91e-05 | 8.33e-04 | 6.98e-04 | 43 |
hsa051327 | Colorectum | MSI-H | Salmonella infection | 43/797 | 249/8465 | 5.91e-05 | 8.33e-04 | 6.98e-04 | 43 |
hsa051328 | Colorectum | FAP | Salmonella infection | 67/1404 | 249/8465 | 2.04e-05 | 2.52e-04 | 1.53e-04 | 67 |
hsa051329 | Colorectum | FAP | Salmonella infection | 67/1404 | 249/8465 | 2.04e-05 | 2.52e-04 | 1.53e-04 | 67 |
hsa0513210 | Colorectum | CRC | Salmonella infection | 48/1091 | 249/8465 | 2.43e-03 | 1.69e-02 | 1.15e-02 | 48 |
hsa0513211 | Colorectum | CRC | Salmonella infection | 48/1091 | 249/8465 | 2.43e-03 | 1.69e-02 | 1.15e-02 | 48 |
hsa0513226 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
hsa05132112 | Endometrium | AEH | Salmonella infection | 71/1197 | 249/8465 | 1.69e-09 | 3.44e-08 | 2.52e-08 | 71 |
hsa0513227 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
hsa0513236 | Endometrium | EEC | Salmonella infection | 71/1237 | 249/8465 | 7.11e-09 | 1.30e-07 | 9.69e-08 | 71 |
hsa0513239 | Esophagus | HGIN | Salmonella infection | 69/1383 | 249/8465 | 3.02e-06 | 4.47e-05 | 3.55e-05 | 69 |
hsa05132115 | Esophagus | HGIN | Salmonella infection | 69/1383 | 249/8465 | 3.02e-06 | 4.47e-05 | 3.55e-05 | 69 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EXOC4 | SNV | Missense_Mutation | rs200509714 | c.2801N>A | p.Arg934His | p.R934H | Q96A65 | protein_coding | deleterious(0) | possibly_damaging(0.664) | TCGA-A1-A0SQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | ac | SD |
EXOC4 | SNV | Missense_Mutation | rs183280115 | c.62N>T | p.Ser21Leu | p.S21L | Q96A65 | protein_coding | deleterious(0) | benign(0.444) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
EXOC4 | SNV | Missense_Mutation | novel | c.1051N>T | p.Ala351Ser | p.A351S | Q96A65 | protein_coding | tolerated(0.42) | benign(0.091) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
EXOC4 | SNV | Missense_Mutation | rs183280115 | c.62N>T | p.Ser21Leu | p.S21L | Q96A65 | protein_coding | deleterious(0) | benign(0.444) | TCGA-AC-A3YI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
EXOC4 | SNV | Missense_Mutation | rs183280115 | c.62N>T | p.Ser21Leu | p.S21L | Q96A65 | protein_coding | deleterious(0) | benign(0.444) | TCGA-AO-A12D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
EXOC4 | SNV | Missense_Mutation | c.2683N>A | p.Ala895Thr | p.A895T | Q96A65 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-AQ-A04J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
EXOC4 | SNV | Missense_Mutation | c.1243N>G | p.Gln415Glu | p.Q415E | Q96A65 | protein_coding | tolerated(0.85) | benign(0.258) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
EXOC4 | SNV | Missense_Mutation | novel | c.1055N>A | p.Val352Glu | p.V352E | Q96A65 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-E2-A1LE-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | herceptin | PD |
EXOC4 | SNV | Missense_Mutation | novel | c.1537N>T | p.Ala513Ser | p.A513S | Q96A65 | protein_coding | tolerated(0.36) | benign(0.003) | TCGA-OL-A6VQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EXOC4 | insertion | Frame_Shift_Ins | novel | c.2634_2635insCCTC | p.Gln879ProfsTer30 | p.Q879Pfs*30 | Q96A65 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |